• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估功能障碍/恢复与抑郁严重程度的关系:一项汇总分析。

Assessing the relationship between functional impairment/recovery and depression severity: a pooled analysis.

机构信息

Pfizer Inc., Collegeville, Pennsylvania 19426, USA.

出版信息

Int Clin Psychopharmacol. 2012 Jan;27(1):1-7. doi: 10.1097/YIC.0b013e32834c2488.

DOI:10.1097/YIC.0b013e32834c2488
PMID:21971533
Abstract

The objective of this study was to explore the relationship between assessments of functional impairment, emotional well-being, and depression symptoms. Data were pooled from 3530 outpatients with major depressive disorder enrolled in 10 desvenlafaxine clinical trials. The primary outcome measures included (a) the 17-item Hamilton Rating Scale for Depression (HAM-D17) as a measure of depressive symptom severity and (b) the Sheehan Disability Scale (SDS) and five-item World Health Organization Well-Being Index (WHO-5) as measures of functional impairment and well-being. A linear regression model was used to identify the SDS and WHO-5 values that equate to the predetermined clinically relevant three-point difference between active treatment and placebo on the HAM-D17. A receiver operating characteristic analysis was conducted to determine the SDS score that equates to a remission of depression symptoms (i.e. HAM-D17≤7). An approximate three-point difference between active treatment and placebo on the SDS (2.8) and WHO-5 (2.5) was determined to be clinically relevant in relation to improvements in depressive symptoms. An SDS of less than or equal to 7 was equivalent to a remission of depression symptoms, providing a definition of functional remission. A better understanding of the relationship between depressive symptoms and functional impairment and well-being may provide clinicians with a more comprehensive means of assessing treatment effects in major depressive disorder.

摘要

这项研究的目的是探讨功能障碍评估、情绪健康和抑郁症状之间的关系。数据来自 10 项去甲文拉法辛临床研究中的 3530 名重度抑郁症门诊患者。主要结局指标包括:(a) 汉密尔顿抑郁量表 17 项版本(HAM-D17),用于评估抑郁症状严重程度;(b) 舍恩残疾量表(SDS)和五项世界卫生组织幸福指数(WHO-5),用于评估功能障碍和幸福感。线性回归模型用于确定 SDS 和 WHO-5 的值,这些值与 HAM-D17 上活性治疗与安慰剂之间预定的临床相关的三分差异相对应。进行了接收器工作特征分析,以确定 SDS 评分,该评分与抑郁症状缓解(即 HAM-D17≤7)相对应。SDS(2.8)和 WHO-5(2.5)上活性治疗与安慰剂之间约三分的差异被确定与抑郁症状的改善相关具有临床意义。SDS 小于或等于 7 等同于抑郁症状的缓解,为功能缓解提供了定义。更好地了解抑郁症状与功能障碍和幸福感之间的关系,可能为临床医生提供一种更全面的评估重度抑郁症治疗效果的方法。

相似文献

1
Assessing the relationship between functional impairment/recovery and depression severity: a pooled analysis.评估功能障碍/恢复与抑郁严重程度的关系:一项汇总分析。
Int Clin Psychopharmacol. 2012 Jan;27(1):1-7. doi: 10.1097/YIC.0b013e32834c2488.
2
Predictors of functional response and remission with desvenlafaxine 50 mg/d in patients with major depressive disorder.度洛西汀50毫克/天治疗重度抑郁症患者功能反应和缓解的预测因素
CNS Spectr. 2014 Dec;19(6):519-27. doi: 10.1017/S1092852914000066. Epub 2014 Feb 26.
3
BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.接受度文拉法辛治疗的抑郁患者的 BDNF、白细胞介素-6 和唾液皮质醇水平。
Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:86-91. doi: 10.1016/j.pnpbp.2013.09.016. Epub 2013 Oct 2.
4
Early improvement in depressive symptoms with desvenlafaxine 50 mg/d as a predictor of treatment success in patients with major depressive disorder.度洛西汀 50mg/d 早期改善抑郁症状可预测重度抑郁症患者的治疗成功。
J Clin Psychopharmacol. 2014 Feb;34(1):57-65. doi: 10.1097/JCP.0000000000000049.
5
A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women.度洛西汀治疗围绝经期和绝经后妇女重度抑郁症疗效的汇总分析。
J Womens Health (Larchmt). 2015 Apr;24(4):281-90. doi: 10.1089/jwh.2014.4900.
6
Post hoc analysis of the efficacy and safety of desvenlafaxine 50 mg/day in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.在一项针对患有重度抑郁症的围绝经期和绝经后女性的随机、安慰剂对照研究中,对每日50毫克去甲文拉法辛的疗效和安全性进行的事后分析。
Menopause. 2014 Aug;21(8):799-806. doi: 10.1097/GME.0000000000000178.
7
Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.度洛西汀50毫克/天和100毫克/天治疗重度抑郁症:一项为期8周的III期多中心随机双盲安慰剂对照平行组试验及三项研究的事后汇总分析。
Clin Ther. 2009 Jun;31 Pt 1:1405-23. doi: 10.1016/j.clinthera.2009.07.006.
8
Efficacy of desvenlafaxine 50 mg compared with placebo in patients with moderate or severe major depressive disorder: a pooled analysis of six randomized, double-blind, placebo-controlled studies.度洛西汀 50 毫克与安慰剂在中重度重度抑郁症患者中的疗效比较:六项随机、双盲、安慰剂对照研究的汇总分析。
Int Clin Psychopharmacol. 2013 Nov;28(6):312-21. doi: 10.1097/YIC.0b013e3283638fbd.
9
Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.在对急性治疗未能应答的绝经后女性抑郁症患者中进行的安非他酮开放性治疗。
CNS Drugs. 2011 Mar;25(3):227-38. doi: 10.2165/11586460-000000000-00000.
10
A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder.一项关于琥珀酸去甲文拉法辛治疗重度抑郁症疗效和安全性的双盲、安慰剂对照研究。
J Clin Psychiatry. 2007 May;68(5):677-88. doi: 10.4088/jcp.v68n0504.

引用本文的文献

1
Systematic Review of the Use of the WHO-5 Well-Being Index Across Different Disease Areas.世界卫生组织-5福祉指数在不同疾病领域应用的系统评价。
Adv Ther. 2025 Aug;42(8):3657-3677. doi: 10.1007/s12325-025-03266-9. Epub 2025 Jun 12.
2
Expanding first-line options for depression: Protocol of a pragmatic comparative effectiveness trial of yoga vs. behavioral activation (the COMPARE study).拓展抑郁症的一线治疗选择:瑜伽与行为激活实用比较疗效试验方案(COMPARE研究)
PLoS One. 2025 Jan 6;20(1):e0315506. doi: 10.1371/journal.pone.0315506. eCollection 2025.
3
Web-Based Mindfulness-Based Interventions for Well-being: Randomized Comparative Effectiveness Trial.
基于网络的正念干预对幸福感的影响:随机对照有效性试验。
J Med Internet Res. 2022 Sep 12;24(9):e35620. doi: 10.2196/35620.
4
Success4life Youth Empowerment for Promoting Well-being and Boosting Mental Health: Protocol for an Experimental Study.“成功人生:促进幸福与提升心理健康的青年赋权”:一项实验研究方案
JMIR Res Protoc. 2022 Sep 14;11(9):e38463. doi: 10.2196/38463.
5
Remission of symptoms is not equal to functional recovery: Psychosocial functioning impairment in major depression.症状缓解不等于功能恢复:重度抑郁症中的心理社会功能损害
Front Psychiatry. 2022 Jul 26;13:915689. doi: 10.3389/fpsyt.2022.915689. eCollection 2022.
6
Emotional blunting in patients with depression. Part II: relationship with functioning, well-being, and quality of life.抑郁症患者的情感迟钝。第二部分:与功能、幸福感和生活质量的关系。
Ann Gen Psychiatry. 2022 Jun 20;21(1):20. doi: 10.1186/s12991-022-00392-4.
7
Comorbid mental disorders, depression symptom severity, and role impairment among Veterans initiating depression treatment through the Veterans Health Administration.通过退伍军人健康管理局开始接受抑郁症治疗的退伍军人中的共病精神障碍、抑郁症状严重程度和角色功能损害。
J Affect Disord. 2021 Jul 1;290:227-236. doi: 10.1016/j.jad.2021.04.033. Epub 2021 Apr 27.
8
Functional Impairment in Patients with Panic Disorder.惊恐障碍患者的功能损害
Psychiatry Investig. 2021 May;18(5):434-442. doi: 10.30773/pi.2020.0425. Epub 2021 May 14.
9
Childhood Maltreatment and Its Interaction with Hypothalamic-Pituitary-Adrenal Axis Activity and the Remission Status of Major Depression: Effects on Functionality and Quality of Life.童年期虐待及其与下丘脑-垂体-肾上腺轴活动和重度抑郁症缓解状态的相互作用:对功能和生活质量的影响
Brain Sci. 2021 Apr 13;11(4):495. doi: 10.3390/brainsci11040495.
10
Real-World Evidence from the Integrative Medicine Primary Care Trial (IMPACT): Assessing Patient-Reported Outcomes at Baseline and 12-Month Follow-Up.整合医学初级保健试验(IMPACT)的真实世界证据:评估基线和12个月随访时患者报告的结局
Evid Based Complement Alternat Med. 2019 Jun 26;2019:8595409. doi: 10.1155/2019/8595409. eCollection 2019.